BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12(8): 1175-1181 [PMID: 16534867 DOI: 10.3748/wjg.v12.i8.1175] [Cited by in CrossRef: 190] [Cited by in F6Publishing: 175] [Article Influence: 12.7] [Reference Citation Analysis]
Number Citing Articles
1 Mitsuhashi N, Kobayashi S, Doki T, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, Nozawa S. Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:e189-e197. [PMID: 18466288 DOI: 10.1111/j.1440-1746.2008.05340.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
2 Grizzi F, Franceschini B, Hamrick C, Frezza EE, Cobos E, Chiriva-Internati M. Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med 2007;5:3. [PMID: 17244360 DOI: 10.1186/1479-5876-5-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
3 Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, McKeegan EM, Dowell B, Pedersen M, Qin Q, Qian J, Scappaticci FA, Ricker JL, Carlson DM, Yong WP. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer. 2013;119:380-387. [PMID: 22833179 DOI: 10.1002/cncr.27758] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 7.7] [Reference Citation Analysis]
4 Nassar ES, Elkalbashawy YA, Kamal A, Zakaria NHE. Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development. Clin Exp Hepatol 2021;7:74-8. [PMID: 34027118 DOI: 10.5114/ceh.2021.104385] [Reference Citation Analysis]
5 Gan Y, Liang Q, Song X. Diagnostic value of alpha-L-fucosidase for hepatocellular carcinoma: a meta-analysis. Tumour Biol. 2014;35:3953-3960. [PMID: 24395655 DOI: 10.1007/s13277-013-1563-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
6 Fu S, Qi C, Xiao W, Li S, Peng B, Liang L. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection. Surgery 2013;154:536-44. [DOI: 10.1016/j.surg.2013.02.014] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 6.4] [Reference Citation Analysis]
7 Liu Y, Li K, Ren Z, Li S, Zhang H, Fan Q. Clinical implication of elevated human cervical cancer oncogene-1 expression in esophageal squamous cell carcinoma. J Histochem Cytochem 2012;60:512-20. [PMID: 22511601 DOI: 10.1369/0022155412444437] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
8 Saxena R, Chawla YK, Verma I, Kaur J. IL-6(-572/-597) polymorphism and expression in HBV disease chronicity in an Indian population. Am J Hum Biol. 2014;26:549-555. [PMID: 24841049 DOI: 10.1002/ajhb.22562] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
9 Wu W, Yao D, Qiu L, Gu X, Wu X. Quantitative analysis of hepatoma-specific α-fetoprotein (HS-AFP) by a new mini-column affinity chromatography and its clinical value in diagnosis of hepatocellular carcinoma. Chin -Ger J Clin Oncol 2008;7:131-4. [DOI: 10.1007/s10330-007-0167-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009;15:1301-14. [PMID: 19294759 DOI: 10.3748/wjg.15.1301] [Cited by in CrossRef: 101] [Cited by in F6Publishing: 82] [Article Influence: 8.4] [Reference Citation Analysis]
11 Kang YH, Park MY, Yoon DY, Han SR, Lee CI, Ji NY, Myung PK, Lee HG, Kim JW, Yeom YI, Jang YJ, Ahn DK, Kim JW, Song EY. Dysregulation of overexpressed IL-32α in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-κB and Bcl-2. Cancer Lett 2012;318:226-33. [PMID: 22198481 DOI: 10.1016/j.canlet.2011.12.023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
12 Kuang Z, Huang R, Yang Z, Lv Z, Chen X, Xu F, Yi YH, Wu J, Huang RP. Quantitative screening of serum protein biomarkers by reverse phase protein arrays. Oncotarget 2018;9:32624-41. [PMID: 30220970 DOI: 10.18632/oncotarget.25976] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
13 Thulin P, Nordahl G, Gry M, Yimer G, Aklillu E, Makonnen E, Aderaye G, Lindquist L, Mattsson CM, Ekblom B, Antoine DJ, Park BK, Linder S, Harrill AH, Watkins PB, Glinghammar B, Schuppe-Koistinen I. Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts.Liver Int. 2014;34:367-378. [PMID: 24118944 DOI: 10.1111/liv.12322] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
14 Pang RWC, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RTP. Biology of Hepatocellular Carcinoma. Ann Surg Oncol 2008;15:962-71. [DOI: 10.1245/s10434-007-9730-z] [Cited by in Crossref: 122] [Cited by in F6Publishing: 112] [Article Influence: 9.4] [Reference Citation Analysis]
15 Huang Z, Zhou B, Li Z, Liu C, Zheng C, Zeng R, Hong C, Xu L, Li E, Peng Y, Xu Y. Serum interleukin-8 as a potential diagnostic biomarker in esophageal squamous cell carcinoma. Cancer Biomark 2020;29:139-49. [PMID: 32623391 DOI: 10.3233/CBM-201687] [Reference Citation Analysis]
16 Zhang YJ, Chen JW, He XS, Zhang HZ, Ling YH, Wen JH, Deng WH, Li P, Yun JP, Xie D, Cai MY. SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas. EBioMedicine 2018;28:62-9. [PMID: 29396302 DOI: 10.1016/j.ebiom.2018.01.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
17 Na K, Lee EY, Lee HJ, Kim KY, Lee H, Jeong SK, Jeong AS, Cho SY, Kim SA, Song SY, Kim KS, Cho SW, Kim H, Paik YK. Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma. Proteomics 2009;9:3989-99. [PMID: 19658107 DOI: 10.1002/pmic.200900105] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 5.7] [Reference Citation Analysis]
18 Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, Vanhooren V, Wang L, Zhuang H, Callewaert N, Libert C, Contreras R, Chen C. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology. 2007;46:1426-1435. [PMID: 17683101 DOI: 10.1002/hep.21855] [Cited by in Crossref: 120] [Cited by in F6Publishing: 118] [Article Influence: 8.6] [Reference Citation Analysis]
19 Park H, Park JY. Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma. Biomed Res Int. 2013;2013:310427. [PMID: 24455683 DOI: 10.1155/2013/310427] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
20 Hussein TD. Serological tumor markers of hepatocellular carcinoma: a meta-analysis. Int J Biol Markers 2015;30:e32-42. [PMID: 25450646 DOI: 10.5301/jbm.5000119] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
21 Heiat M, Negahdary M. Sensitive diagnosis of alpha-fetoprotein by a label free nanoaptasensor designed by modified Au electrode with spindle-shaped gold nanostructure. Microchemical Journal 2019;148:456-66. [DOI: 10.1016/j.microc.2019.05.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
22 Shalably NM, Badawi R, Hawash N, Abd-elsalam S, Elkhalawany W, Hameed AAE, Alkassas GE. Evaluation of Fucosylated Haptoglobin as a Diagnostic Biomarker for Hepatocellular Carcinoma in Egypt. TOBIOMJ 2019;9:31-7. [DOI: 10.2174/1875318301909010031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ye Q, Ling S, Zheng S, Xu X. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019;18:114. [PMID: 31269959 DOI: 10.1186/s12943-019-1043-x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 33.0] [Reference Citation Analysis]
24 Peng Q, Chunfang G, Meng F, Qiang J, Yunpeng Z, Yan L, Xiaojuan S. Establishment of a real-time PCR for quantifying transforming growth factor beta1 in blood of hepatocellular carcinoma patients. Journal of Medical Colleges of PLA 2008;23:228-36. [DOI: 10.1016/s1000-1948(08)60047-7] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
25 Krause GC, Lima KG, Haute GV, Schuster AD, Dias HB, Mesquita FC, Pedrazza L, Marczak ES, Basso BS, Velasque AC, Martha BA, Nunes FB, Donadio MVF, de Oliveira JR. Fructose-1,6-bisphosphate decreases IL-8 levels and increases the activity of pro-apoptotic proteins in HepG2 cells. Biomedicine & Pharmacotherapy 2017;89:358-65. [DOI: 10.1016/j.biopha.2017.01.178] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
26 Kiran M, Chawla YK, Kaur J. Glutathione-S-transferase and microsomal epoxide hydrolase polymorphism and viral-related hepatocellular carcinoma risk in India. DNA Cell Biol. 2008;27:687-694. [PMID: 18816171 DOI: 10.1089/dna.2008.0805] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
27 Aguilar-Melero P, Prieto-Álamo MJ, Jurado J, Holmgren A, Pueyo C. Proteomics in HepG2 hepatocarcinoma cells with stably silenced expression of PRDX1. J Proteomics. 2013;79:161-171. [PMID: 23277276 DOI: 10.1016/j.jprot.2012.12.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
28 Kim YS, Kang KN, Shin YS, Lee JE, Jang JY, Kim CW. Diagnostic value of combining tumor and inflammatory biomarkers in detecting common cancers in Korea. Clin Chim Acta 2021;516:169-78. [PMID: 33577759 DOI: 10.1016/j.cca.2021.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Chrzanowska A, Graboń W, Mielczarek-Puta M, Barańczyk-Kuźma A. Significance of arginase determination in body fluids of patients with hepatocellular carcinoma and liver cirrhosis before and after surgical treatment. Clin Biochem 2014;47:1056-9. [PMID: 24713397 DOI: 10.1016/j.clinbiochem.2014.03.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
30 Sun L, Su Y, Liu X, Xu M, Chen X, Zhu Y, Guo Z, Bai T, Dong L, Wei C, Cai X, He B, Pan Y, Sun H, Wang S. Serum and exosome long non coding RNAs as potential biomarkers for hepatocellular carcinoma. J Cancer. 2018;9:2631-2639. [PMID: 30087703 DOI: 10.7150/jca.24978] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 17.7] [Reference Citation Analysis]
31 Yang H, Xiong F, Qi R, Liu Z, Lin M, Rui J, Su J, Zhou R. LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. J Surg Oncol 2010;101:363-9. [DOI: 10.1002/jso.21489] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
32 Tung EK, Mak CK, Fatima S, Lo RC, Zhao H, Zhang C, Dai H, Poon RT, Yuen MF, Lai CL. Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int. 2011;31:1494-1504. [PMID: 21955977 DOI: 10.1111/j.1478-3231.2011.02597.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 7.4] [Reference Citation Analysis]
33 Kang YH, Ji NY, Lee CI, Lee HG, Kim JW, Yeom YI, Kim DG, Yoon SK, Kim JW, Park PJ, Song EY. ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma. Amino Acids 2011;40:1003-13. [PMID: 20821239 DOI: 10.1007/s00726-010-0729-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
34 Di Michele M, Marcone S, Cicchillitti L, Della Corte A, Ferlini C, Scambia G, Donati MB, Rotilio D. Glycoproteomics of paclitaxel resistance in human epithelial ovarian cancer cell lines: towards the identification of putative biomarkers. J Proteomics 2010;73:879-98. [PMID: 19951750 DOI: 10.1016/j.jprot.2009.11.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
35 Guo Z, Wang J, Li L, Liu R, Fang J, Tie B. Value of miR-1271 and glypican-3 in evaluating the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. World J Clin Cases 2020;8:3493-502. [PMID: 32913856 DOI: 10.12998/wjcc.v8.i16.3493] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Metwaly HA, Al-Gayyar MM, Eletreby S, Ebrahim MA, El-Shishtawy MM. Relevance of serum levels of interleukin-6 and syndecan-1 in patients with hepatocellular carcinoma. Sci Pharm. 2012;80:179-188. [PMID: 22396913 DOI: 10.3797/scipharm.1110-07] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
37 Gurakar A, Ma M, Garonzik-wang J, Kim A, Anders RA, Oshima K, Georgiades C, Gurakar M, Ottmann S, Cameron AM, Philosophe B, Saberi B. Clinicopathological Distinction of Low-AFP-Secreting vs. High-AFP-Secreting Hepatocellular Carcinomas. Annals of Hepatology 2018;17:1052-66. [DOI: 10.5604/01.3001.0012.7206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
38 Morris SM, Baek JY, Koszarek A, Kanngurn S, Knoblaugh SE, Grady WM. Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss. Hepatology 2012;55:121-31. [PMID: 21898503 DOI: 10.1002/hep.24653] [Reference Citation Analysis]
39 Kim JU, Shariff MI, Crossey MM, Gomez-Romero M, Holmes E, Cox IJ, Fye HK, Njie R, Taylor-Robinson SD. Hepatocellular carcinoma: Review of disease and tumor biomarkers. World J Hepatol. 2016;8:471-484. [PMID: 27057305 DOI: 10.4254/wjh.v8.i10.471] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
40 Aglan HA, Ahmed HH, El-Toumy SA, Mahmoud NS. Gallic acid against hepatocellular carcinoma: An integrated scheme of the potential mechanisms of action from in vivo study. Tumour Biol 2017;39:1010428317699127. [PMID: 28618930 DOI: 10.1177/1010428317699127] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
41 Hagag NA, Ali YBM, Elsharawy AA, Talaat RM. Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression. J Gastrointest Cancer. 2020;51:234-241. [PMID: 31028536 DOI: 10.1007/s12029-019-00234-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
42 Tsai M, Wang J, Hung C, Kee K, Yen Y, Lee C, Hu T, Chen C, Lu S. Favorable α-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation: α-Fetoprotein after radiofrequency ablation. Journal of Gastroenterology and Hepatology 2010;25:605-12. [DOI: 10.1111/j.1440-1746.2009.06115.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
43 Zhao H, Li Y, Hu Y. Nanotechnologies in glycoproteomics. Clin Proteomics 2014;11:21. [PMID: 24940182 DOI: 10.1186/1559-0275-11-21] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
44 Bachert C, Fimmel C, Linstedt AD. Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic. 2007;8:1415-1423. [PMID: 17662025 DOI: 10.1111/j.1600-0854.2007.00621.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 4.8] [Reference Citation Analysis]
45 Intra J, Perotti ME, Pavesi G, Horner D. Comparative and phylogenetic analysis of alpha-L-fucosidase genes. Gene 2007;392:34-46. [PMID: 17175120 DOI: 10.1016/j.gene.2006.11.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
46 Nagel T, Klaus F, Ibanez IG, Wege H, Lohse A, Meyer B. Fast and facile analysis of glycosylation and phosphorylation of fibrinogen from human plasma-correlation with liver cancer and liver cirrhosis. Anal Bioanal Chem 2018;410:7965-77. [PMID: 30397756 DOI: 10.1007/s00216-018-1418-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
47 Qiao M, Pardee AB. Biomarkers, regerons, and pathways to lethal cancer. J Cell Biochem 2007;102:1076-86. [PMID: 17957698 DOI: 10.1002/jcb.21534] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Kim KH, Kim JY, Yoo JS. Mass spectrometry analysis of glycoprotein biomarkers in human blood of hepatocellular carcinoma. Expert Review of Proteomics 2019;16:553-68. [DOI: 10.1080/14789450.2019.1626235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
49 He Y, Lu H, Zhang L. Serum AFP levels in patients suffering from 47 different types of cancers and noncancer diseases. Prog Mol Biol Transl Sci 2019;162:199-212. [PMID: 30905450 DOI: 10.1016/bs.pmbts.2019.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
50 Fan F, Shen H, Zhang G, Jiang X, Kang X. Chemiluminescence immunoassay based on microfluidic chips for α-fetoprotein. Clinica Chimica Acta 2014;431:113-7. [DOI: 10.1016/j.cca.2014.02.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
51 Chun S, Rhie SY, Ki CS, Kim JE, Park HD. Evaluation of alpha-fetoprotein as a screening marker for hepatocellular carcinoma in hepatitis prevalent areas. Ann Hepatol 2015;14:882-8. [PMID: 26436360 DOI: 10.5604/16652681.1171776] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
52 Ghosh S, Dungdung SR, Choudhury ST, Chakraborty S, Das N. Mitochondria protection with ginkgolide B-loaded polymeric nanocapsules prevents diethylnitrosamine-induced hepatocarcinoma in rats. Nanomedicine 2014;9:441-56. [DOI: 10.2217/nnm.13.56] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
53 Liu XF, Hu ZD, Liu XC, Cao Y, Ding CM, Hu CJ. Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Biochem. 2014;47:196-200. [PMID: 24362268 DOI: 10.1016/j.clinbiochem.2013.12.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
54 Patil M, Sheth KA, Adarsh CK. Elevated alpha fetoprotein, no hepatocellular carcinoma. J Clin Exp Hepatol 2013;3:162-4. [PMID: 25755491 DOI: 10.1016/j.jceh.2013.02.246] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
55 Lui KY, Peng HR, Lin JR, Qiu CH, Chen HA, Fu RD, Cai CJ, Lu MQ. Pseudogene integrator complex subunit 6 pseudogene 1 (INTS6P1) as a novel plasma-based biomarker for hepatocellular carcinoma screening. Tumour Biol 2016;37:1253-60. [PMID: 26286832 DOI: 10.1007/s13277-015-3899-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
56 Hussein YM, Morad FE, Gameel MA, Emam WA, El Sawy WH, El Tarhouny SA, Bayomy ES, Raafat N. MAGE-4 gene m-RNA and TGF in blood as potential biochemical markers for HCC in HCV-infected patients.Med Oncol. 2012;29:3055-3062. [PMID: 22653756 DOI: 10.1007/s12032-012-0257-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
57 Demir M, Grünewald F, Lang S, Schramm C, Bowe A, Mück V, Kütting F, Goeser T, Steffen HM. Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients. Medicine (Baltimore) 2016;95:e4602. [PMID: 27661015 DOI: 10.1097/MD.0000000000004602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma. Mol Clin Oncol. 2013;1:593-598. [PMID: 24649215 DOI: 10.3892/mco.2013.119] [Cited by in Crossref: 135] [Cited by in F6Publishing: 120] [Article Influence: 16.9] [Reference Citation Analysis]
59 Zhu J, Jiang F, Ni HB, Xiao MB, Chen BY, Ni WK, Lu CH, Ni RZ. Combined analysis of serum γ-glutamyl transferase isoenzyme II, α-L-fucosidase and α-fetoprotein detected using a commercial kit in the diagnosis of hepatocellular carcinoma. Exp Ther Med. 2013;5:89-94. [PMID: 23251247 DOI: 10.3892/etm.2012.783] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
60 Zhang X, Ren X, Cao W, Li Y, Du B, Wei Q. Simultaneous electrochemical immunosensor based on water-soluble polythiophene derivative and functionalized magnetic material. Analytica Chimica Acta 2014;845:85-91. [DOI: 10.1016/j.aca.2014.05.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
61 Nuevo-Gonzalez JA, Cano-Ballesteros JC, Lopez B, Andueza-Lillo JA, Audibert L. Alpha-Fetoprotein-Producing Extrahepatic Tumor: Clinical and Histopathological Significance of a Case. J Gastrointest Cancer. 2012;43 Suppl 1:28-31. [PMID: 21826411 DOI: 10.1007/s12029-011-9310-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
62 Chiappini F. Circulating tumor cells measurements in hepatocellular carcinoma. Int J Hepatol. 2012;2012:684802. [PMID: 22690340 DOI: 10.1155/2012/684802] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
63 Yao Z, Jia C, Tai Y, Liang H, Zhong Z, Xiong Z, Deng M, Zhang Q. Serum exosomal long noncoding RNAs lnc-FAM72D-3 and lnc-EPC1-4 as diagnostic biomarkers for hepatocellular carcinoma. Aging (Albany NY) 2020;12:11843-63. [PMID: 32554864 DOI: 10.18632/aging.103355] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
64 Roderburg C, Bubenzer J, Spannbauer M, do O N, Mahnken A, Ludde T, Trautwein C, Tischendorf JJ. Long-term survival of a HCC-patient with severe liver dysfunction treated with sorafenib. World J Hepatol 2010;2:239-42. [PMID: 21161003 DOI: 10.4254/wjh.v2.i6.239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
65 Rahat B, Kiran M, Saxena R, Chawla YK, Sharma RR, Kaur J. Microsomal Epoxide Hydrolase Polymorphisms and Haplotypes as Determinants of Hepatitis B Virusand Hepatitis C Virus-related Liver Disease in Indian Population. J Clin Exp Hepatol 2012;2:104-11. [PMID: 25755418 DOI: 10.1016/S0973-6883(12)60097-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
66 Ahmed HH, Shousha WG, Shalby AB, El-mezayen HA, Ismaiel NN, Mahmoud NS. Curcumin: a unique antioxidant offers a multimechanistic approach for management of hepatocellular carcinoma in rat model. Tumor Biol 2015;36:1667-78. [DOI: 10.1007/s13277-014-2767-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
67 Cha H, Lee EJ, Seong J. Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy. World J Gastroenterol 2017;23:2077-85. [PMID: 28373775 DOI: 10.3748/wjg.v23.i11.2077] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
68 Asimakopoulou A, Vucur M, Luedde T, Schneiders S, Kalampoka S, Weiss TS, Weiskirchen R. Perilipin 5 and Lipocalin 2 Expression in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E385. [PMID: 30893876 DOI: 10.3390/cancers11030385] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
69 Sun Y, Zheng X, Yuan H, Chen G, Ouyang J, Liu J, Liu X, Xing X, Zhao B. Proteomic analyses reveal divergent ubiquitylation patterns in hepatocellula carcinoma cell lines with different metastasis potential. J Proteomics 2020;225:103834. [PMID: 32454254 DOI: 10.1016/j.jprot.2020.103834] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
70 Abdel-hamid NM, Abouzied MM, Nazmy MH, Fawzy MA, Gerges AS. A suggested guiding panel of seromarkers for efficient discrimination between primary and secondary human hepatocarcinoma. Tumor Biol 2016;37:2539-46. [DOI: 10.1007/s13277-015-4025-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
71 Yu J, Ma Q, Zhang B, Ma R, Xu X, Li M, Xu W, Li M. Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis. Sci China Life Sci 2013;56:234-9. [DOI: 10.1007/s11427-013-4451-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
72 Othman MS, Aref AM, Mohamed AA, Ibrahim WA. Serum Levels of Interleukin-6 and Interleukin-10 as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients. ISRN Hepatol 2013;2013:412317. [PMID: 27335826 DOI: 10.1155/2013/412317] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
73 Park WH, Shim JH, Han SB, Won HJ, Shin YM, Kim KM, Lim YS, Lee HC. Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol 2012;23:927-36. [PMID: 22633621 DOI: 10.1016/j.jvir.2012.04.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
74 Zhang Z, Zhu J, Huang Y, Li W, Cheng H. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway. Diagn Pathol 2018;13:85. [PMID: 30390677 DOI: 10.1186/s13000-018-0763-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
75 Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266-280. [PMID: 18628926 DOI: 10.1080/08998280.2008.11928410] [Cited by in Crossref: 105] [Cited by in F6Publishing: 97] [Article Influence: 10.5] [Reference Citation Analysis]
76 Kunutsor SK, Apekey TA, Van Hemelrijck M, Calori G, Perseghin G. Gamma glutamyltransferase, alanine aminotransferase and risk of cancer: systematic review and meta-analysis. Int J Cancer. 2015;136:1162-1170. [PMID: 25043373 DOI: 10.1002/ijc.29084] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
77 Pulati N, Zhang Z, Gulimilamu A, Qi X, Yang J. HPV16 + ‐miRNAs in cervical cancer and the anti‐tumor role played by miR‐5701. J Gene Med 2019;21. [DOI: 10.1002/jgm.3126] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
78 Zou K, Ju J, Xie H. Novel tumor-associated antigen of hepatocellular carcinoma defined by monoclonal antibody E4-65. Acta Biochim Biophys Sin (Shanghai) 2007;39:359-65. [PMID: 17492133 DOI: 10.1111/j.1745-7270.2007.00288.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
79 Song J, Lee YN, Kim YS, Kim SG, Jin SJ, Park JM, Choi GS, Chung JC, Lee MH, Cho YH, Choi MH, Kim DC, Choi HJ, Moon JH, Lee SH, Jeong SW, Jang JY, Kim HS, Kim BS. Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors. Nuclear Medicine Communications 2015;36:319-27. [DOI: 10.1097/mnm.0000000000000254] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
80 Thumanu K, Sangrajrang S, Khuhaprema T, Kalalak A, Tanthanuch W, Pongpiachan S, Heraud P. Diagnosis of liver cancer from blood sera using FTIR microspectroscopy: a preliminary study. J Biophotonics 2014;7:222-31. [PMID: 24639420 DOI: 10.1002/jbio.201300183] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 4.9] [Reference Citation Analysis]
81 Park SY, Han J, Kim JB, Yang M, Kim YJ, Lim H, An SY, Kim J. Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma. European Journal of Cancer 2014;50:341-50. [DOI: 10.1016/j.ejca.2013.09.021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
82 Soliman HH, Nagy H, Kotb N, Alm El-Din MA. The role of chemokine CC ligand 20 in patients with liver cirrhosis and hepatocellular carcinoma. Int J Biol Markers. 2012;27:e125-e131. [PMID: 22388957 DOI: 10.5301/jbm.2012.9097] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
83 Lu H, Zhang H, Xiao Y, Chingin K, Dai C, Wei F, Wang N, Frankevich V, Chagovets V, Zhou F, Chen H. Comparative study of alterations in phospholipid profiles upon liver cancer in humans and mice. Analyst 2020;145:6470-7. [PMID: 32856629 DOI: 10.1039/d0an01080d] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
84 Morris SM, Baek JY, Koszarek A, Kanngurn S, Knoblaugh SE, Grady WM. Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss. Hepatology 2012;55:121-31. [PMID: 21898503 DOI: 10.1002/hep.24653] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
85 Saxena R, Chawla YK, Verma I, Kaur J. IFN-γ (+874) and not TNF-α (-308) is associated with HBV-HCC risk in India. Mol Cell Biochem. 2014;385:297-307. [PMID: 24101445 DOI: 10.1007/s11010-013-1838-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
86 Younis YS, Alegaily HS, Elagawy W, Semeya AA, Abo-Amer YE, El-Abgeegy M, Mostafa SM, Elsergany HF, Abd-Elsalam S. Serum Dickopff 1 as a Novel Biomarker in Hepatocellular Carcinoma Diagnosis and Follow Up After Ablative Therapy. Cancer Manag Res 2019;11:10555-62. [PMID: 31908527 DOI: 10.2147/CMAR.S218532] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
87 Suryatenggara J, Wibowo H, Atmodjo WL, Mathew G. Characterization of alpha-fetoprotein effects on dendritic cell and its function as effector immune response activator. J Hepatocell Carcinoma 2017;4:139-51. [PMID: 29238703 DOI: 10.2147/JHC.S139070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 El-Tonsy MM, Hussein HM, Helal Tel-S, Tawfik RA, Koriem KM, Hussein HM. Schistosoma mansoni infection: is it a risk factor for development of hepatocellular carcinoma? Acta Trop 2013;128:542-7. [PMID: 23932944 DOI: 10.1016/j.actatropica.2013.07.024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
89 Kiran M, Chawla YK, Jain M, Kaur J. Haplotypes of microsomal epoxide hydrolase and x-ray cross-complementing group 1 genes in Indian hepatocellular carcinoma patients. DNA Cell Biol 2009;28:573-7. [PMID: 19754350 DOI: 10.1089/dna.2009.0921] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
90 Hu G, Tuomilehto J, Pukkala E, Hakulinen T, Antikainen R, Vartiainen E, Jousilahti P. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology. 2008;48:129-136. [PMID: 18537182 DOI: 10.1002/hep.22320] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 4.6] [Reference Citation Analysis]
91 Matsuda Y, Yamagiwa Y, Fukushima K, Ueno Y, Shimosegawa T. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res. 2008;38:1098-1111. [PMID: 18684128 DOI: 10.1111/j.1872-034x.2008.00387.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
92 Singhal A, Jayaraman M, Dhanasekaran DN, Kohli V. Molecular and serum markers in hepatocellular carcinoma: Predictive tools for prognosis and recurrence. Critical Reviews in Oncology/Hematology 2012;82:116-40. [DOI: 10.1016/j.critrevonc.2011.05.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
93 Reiter MJ, Costello JE, Schwope RB, Lisanti CJ, Osswald MB. Review of Commonly Used Serum Tumor Markers and Their Relevance for Image Interpretation. J Comput Assist Tomogr 2015;39:825-34. [PMID: 26248153 DOI: 10.1097/RCT.0000000000000297] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
94 Zhang Q, Wang X, Li Z, Lin JM. Evaluation of alpha-fetoprotein (AFP) in human serum by chemiluminescence enzyme immunoassay with magnetic particles and coated tubes as solid phases. Anal Chim Acta 2009;631:212-7. [PMID: 19084628 DOI: 10.1016/j.aca.2008.10.042] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
95 Li X, Wang J, Li W, Huang Z, Fan W, Chen Y, Shen L, Pan T, Wu P, Zhao M. Percutaneous CT-guided radiofrequency ablation for unresectable hepatocellular carcinoma pulmonary metastases. Int J Hyperthermia. 2012;28:721-728. [PMID: 23153217 DOI: 10.3109/02656736.2012.736669] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
96 Teng YW, Mehedint MG, Garrow TA, Zeisel SH. Deletion of betaine-homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas. J Biol Chem. 2011;286:36258-36267. [PMID: 21878621 DOI: 10.1074/jbc.m111.265348] [Cited by in Crossref: 126] [Cited by in F6Publishing: 69] [Article Influence: 12.6] [Reference Citation Analysis]
97 Helal Tel A, Radwan NA, Abdel Kader Z, Helmy NA, Hammad SY. Role of alpha methylacyl-coenzyme A racemase in differentiating hepatocellular carcinoma from dysplastic and nondysplastic liver cell lesions. Ann Diagn Pathol 2012;16:330-4. [PMID: 22542076 DOI: 10.1016/j.anndiagpath.2012.01.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
98 Tian Y, Zhang H. Characterization of disease-associated N-linked glycoproteins. Proteomics 2013;13:504-11. [PMID: 23255236 DOI: 10.1002/pmic.201200333] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
99 Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2010;16:418-424. [PMID: 20101765 DOI: 10.3748/wjg.v16.i4.418] [Cited by in CrossRef: 111] [Cited by in F6Publishing: 102] [Article Influence: 10.1] [Reference Citation Analysis]
100 Cho S, Ryu KM, Hwang YJ, Lee EB. Prognostic factors for pulmonary metastasectomy in the treatment of hepatocellular carcinoma. J Thorac Oncol 2010;5:1251-4. [PMID: 20588200 DOI: 10.1097/JTO.0b013e3181e2fc9b] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
101 Mathew S, Ali A, Abdel-hafiz H, Fatima K, Suhail M, Archunan G, Begum N, Jahangir S, Ilyas M, Chaudhary AG, Al Qahtani M, Mohamad Bazarah S, Qadri I. Biomarkers for virus-induced hepatocellular carcinoma (HCC). Infection, Genetics and Evolution 2014;26:327-39. [DOI: 10.1016/j.meegid.2014.06.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
102 Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res. 2013;1:10. [PMID: 24252133 DOI: 10.1186/2050-7771-1-10] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
103 Kashima M, Yamakado K, Takaki H, Kaminou T, Tanigawa N, Nakatsuka A, Takeda K. Radiofrequency ablation for the treatment of bone metastases from hepatocellular carcinoma. AJR Am J Roentgenol. 2010;194:536-541. [PMID: 20093621 DOI: 10.2214/ajr.09.2975] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
104 Huang H, Wang XP, Li XH, Chen H, Zheng X, Lin JH, Kang T, Zhang L, Chen PS. Prognostic value of pretreatment serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) ratio and gamma glutamyltransferase (GGT) in patients with esophageal squamous cell carcinoma. BMC Cancer 2017;17:544. [PMID: 28806937 DOI: 10.1186/s12885-017-3523-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
105 Li Y, Xu J, Chen L, Zhong WD, Zhang Z, Mi L, Zhang Y, Liao CG, Bian HJ, Jiang JL, Yang XM, Li XY, Fan CM, Zhu P, Fu L, Chen ZN. HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology 2009;54:677-87. [PMID: 19438743 DOI: 10.1111/j.1365-2559.2009.03280.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 105] [Article Influence: 9.4] [Reference Citation Analysis]
106 Senes G, Fanni D, Cois A, Uccheddu A, Faa G. Intratumoral sampling variability in hepatocellular carcinoma: a case report. World J Gastroenterol 2007;13:4019-21. [PMID: 17663522 DOI: 10.3748/wjg.v13.i29.4019] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
107 Li W, Cagle PT, Botero RC, Liang JJ, Zhang Z, Tan D. Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma. J Exp Clin Cancer Res 2008;27:2. [PMID: 18577240 DOI: 10.1186/1756-9966-27-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
108 Singh G, Yoshida EM, Rathi S, Marquez V, Kim P, Erb SR, Salh BS. Biomarkers for hepatocellular cancer. World J Hepatol 2020;12:558-73. [PMID: 33033565 DOI: 10.4254/wjh.v12.i9.558] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
109 Saxena R, Chawla YK, Verma I, Kaur J. Effect of IL-12B, IL-2, TGF-β1, and IL-4 polymorphism and expression on hepatitis B progression. J Interferon Cytokine Res. 2014;34:117-128. [PMID: 24161121 DOI: 10.1089/jir.2013.0043] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
110 Inagaki Y, Xu HL, Hasegawa K, Aoki T, Beck Y, Sugawara Y, Tang W, Kokudo N. Des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma and liver cirrhosis. J Dig Dis. 2011;12:481-488. [PMID: 22118699 DOI: 10.1111/j.1751-2980.2011.00521.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
111 Mocan T, Simão AL, Castro RE, Rodrigues CMP, Słomka A, Wang B, Strassburg C, Wöhler A, Willms AG, Kornek M. Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning? J Clin Med 2020;9:E1541. [PMID: 32443747 DOI: 10.3390/jcm9051541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
112 Hao QQ, Chen GY, Zhang JH, Sheng JH, Gao Y. Diagnostic value of long noncoding RNAs for hepatocellular carcinoma: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 2017;96:e7496. [PMID: 28700498 DOI: 10.1097/md.0000000000007496] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
113 Abdel-Hamid NM, Abdullah AH. Serum histamine and acetylcholine variations as new noninvasive biochemical markers in staging of experimental hepatocellular carcinoma. Clin Exp Med 2019;19:115-20. [PMID: 30460419 DOI: 10.1007/s10238-018-0537-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
114 Wu Y, Xu W, Wang Y, Yuan Y, Yuan R. Silver–graphene oxide nanocomposites as redox probes for electrochemical determination of α-1-fetoprotein. Electrochimica Acta 2013;88:135-40. [DOI: 10.1016/j.electacta.2012.10.081] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
115 Xiao M, Chen Y, Yu H, Wei S, Yu K, Zhao H, Chen R. Analysis of the whole serum proteome using an integrated 2D LC-MS/MS system. Anal Methods 2014;6:7157-60. [DOI: 10.1039/c4ay01274g] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
116 Duvoux C. Transplantation hépatique pour carcinome hépatocellulaire. Gastroentérologie Clinique et Biologique 2006;30:1343-5. [DOI: 10.1016/s0399-8320(06)73551-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
117 Sabherwal Y, Rothman VL, Poon RT, Tuszynski GP. Clinical significance of serum angiocidin levels in hepatocellular carcinoma. Cancer Lett 2007;251:28-35. [PMID: 17188426 DOI: 10.1016/j.canlet.2006.10.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
118 Li N, Zhao L, Guo C, Liu C, Liu Y. Identification of a novel DNA repair-related prognostic signature predicting survival of patients with hepatocellular carcinoma. Cancer Manag Res 2019;11:7473-84. [PMID: 31496805 DOI: 10.2147/CMAR.S204864] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
119 Yuan D, Chen Y, Li X, Li J, Zhao Y, Shen J, Du F, Kaboli PJ, Li M, Wu X, Ji H, Cho CH, Wen Q, Li W, Xiao Z, Chen B. Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis. Int J Biol Sci 2021;17:220-35. [PMID: 33390845 DOI: 10.7150/ijbs.50730] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
120 Hammad LN, Abdelraouf SM, Hassanein FS, Mohamed WA, Schaalan MF. Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: potential biomarkers for a more favorable prognosis? J Immunotoxicol. 2013;10:380-386. [PMID: 23350952 DOI: 10.3109/1547691x.2012.758198] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
121 Raos D, Ulamec M, Katusic Bojanac A, Bulic-Jakus F, Jezek D, Sincic N. Epigenetically inactivated RASSF1A as a tumor biomarker. Bosn J Basic Med Sci 2021;21:386-97. [PMID: 33175673 DOI: 10.17305/bjbms.2020.5219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Evaluation of the "assessment for continuous treatment with hepatic arterial infusion chemotherapy" scoring system in patients with advanced hepatocellular carcinoma. Hepatol Res 2018;48:E87-97. [PMID: 28656680 DOI: 10.1111/hepr.12932] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
123 Aarthy R, Mani S, Velusami S, Sundarsingh S, Rajkumar T. Role of Circulating Cell-Free DNA in Cancers. Mol Diagn Ther 2015;19:339-50. [PMID: 26400814 DOI: 10.1007/s40291-015-0167-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
124 Eldesouky MA, Elbakary MA, Shalaby OE, Shareef MM. Orbital metastasis from hepatocellular carcinoma: report of 6 cases. Ophthalmic Plast Reconstr Surg 2014;30:e78-82. [PMID: 24195986 DOI: 10.1097/IOP.0b013e31829f3a57] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
125 Zhao L, Xie C, Liu D, Li T, Zhang Y, Wan C. Early Detection of Hepatocellular Carcinoma in Patients with Hepatocirrhosis by Soluble B7-H3. J Gastrointest Surg 2017;21:807-12. [PMID: 28243980 DOI: 10.1007/s11605-017-3386-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
126 Owen WE, Roberts RF, Roberts WL. Performance characteristics of the LiBASys® des-gamma-carboxy prothrombin assay. Clinica Chimica Acta 2008;389:183-5. [DOI: 10.1016/j.cca.2007.11.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
127 Jia Z, Wang L, Liu C, Yu Z, Chai L, Zhao M. Evaluation of α-fetoprotein-L3 and Golgi protein 73 detection in diagnosis of hepatocellular carcinoma. Contemp Oncol (Pozn). 2014;18:192-196. [PMID: 25520580 DOI: 10.5114/wo.2014.43157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
128 Abdul-Al HM, Makhlouf HR, Wang G, Goodman ZD. Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum Pathol. 2008;39:209-212. [PMID: 17949778 DOI: 10.1016/j.humpath.2007.06.004] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 4.2] [Reference Citation Analysis]
129 Sugihara T, Tanaka S, Braga-Tanaka I 3rd, Murano H, Nakamura-Murano M, Komura JI. Screening of biomarkers for liver adenoma in low-dose-rate γ-ray-irradiated mice. Int J Radiat Biol 2018;94:315-26. [PMID: 29424599 DOI: 10.1080/09553002.2018.1439193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
130 Han EC, Lee Y, Liao W, Liu Y, Liao H, Jeng L. Direct tissue analysis by MALDI-TOF mass spectrometry in human hepatocellular carcinoma. Clinica Chimica Acta 2011;412:230-9. [DOI: 10.1016/j.cca.2010.09.021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
131 Masuda T, Beppu T, Horino K, Komori H, Hayashi H, Okabe H, Otao R, Horlad H, Ishiko T, Takamori H. Preoperative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma. J Surg Oncol. 2010;102:490-496. [PMID: 19937994 DOI: 10.1002/jso.21451] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
132 Zhang M, Wang L, Zhang H, Cong J, Zhang L. Serum α-l-fucosidase activities are significantly increased in patients with preeclampsia. Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part A. Elsevier; 2019. pp. 349-62. [DOI: 10.1016/bs.pmbts.2018.12.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
133 Liu Z, Ling Q, Wang J, Xie H, Xu X, Zheng S. Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis. Oncol Lett 2013;6:125-9. [PMID: 23946789 DOI: 10.3892/ol.2013.1337] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
134 Li X, Chen B, He M, Xiao G, Hu B. Gold nanoparticle labeling with tyramide signal amplification for highly sensitive detection of alpha fetoprotein in human serum by ICP-MS. Talanta 2018;176:40-6. [DOI: 10.1016/j.talanta.2017.08.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
135 Tátrai P, Somorácz A, Batmunkh E, Schirmacher P, Kiss A, Schaff Z, Nagy P, Kovalszky I. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions. Am J Surg Pathol. 2009;33:874-885. [PMID: 19194276 DOI: 10.1097/pas.0b013e318194b3ea] [Cited by in Crossref: 42] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
136 Farid IM, Hamza IM, El-Abd DM, Mohyi AM, AbdulLatif MM, Aref AT, Hamza DM. Transforming growth factor-β1 gene expression in hepatocellular carcinoma: a preliminary report. Arab J Gastroenterol 2014;15:142-7. [PMID: 25475758 DOI: 10.1016/j.ajg.2014.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
137 Saad-Hussein A, Beshir S, Taha MM, Shahy EM, Shaheen W, Abdel-Shafy EA, Thabet E. Early prediction of liver carcinogenicity due to occupational exposure to pesticides. Mutat Res Genet Toxicol Environ Mutagen 2019;838:46-53. [PMID: 30678827 DOI: 10.1016/j.mrgentox.2018.12.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
138 Kotyza J. Interleukin-8 (CXCL8) in tumor associated non-vascular extracellular fluids: its diagnostic and prognostic values. A review. Int J Biol Markers 2012;27:169-78. [PMID: 22610755 DOI: 10.5301/JBM.2012.9261] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
139 Guo Z, Wu L, Hu Y, Wang S, Li X. Potential-resolved “in-electrode” type electrochemiluminescence immunoassay based on functionalized g-C 3 N 4 nanosheet and Ru-NH 2 for simultaneous determination of dual targets. Biosensors and Bioelectronics 2017;95:27-33. [DOI: 10.1016/j.bios.2017.03.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
140 Wich C, Agaimy A, Strobel D, Wissniowski TT, Hartmann A, Ocker M. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib. World J Gastroenterol 2010;16:3592-6. [PMID: 20653070 DOI: 10.3748/wjg.v16.i28.3592] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
141 Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol. 2016;22:232-252. [PMID: 26755873 DOI: 10.3748/wjg.v22.i1.232] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
142 Lim WY, Goh BT, Khor SM. Microfluidic paper-based analytical devices for potential use in quantitative and direct detection of disease biomarkers in clinical analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2017;1060:424-42. [PMID: 28683395 DOI: 10.1016/j.jchromb.2017.06.040] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 9.5] [Reference Citation Analysis]
143 Chen YW, Pan HB, Tseng HH, Hung YT, Huang JS, Chou CP. Assessment of blood flow in hepatocellular carcinoma: correlations of computed tomography perfusion imaging and circulating angiogenic factors. Int J Mol Sci. 2013;14:17536-17552. [PMID: 23985826 DOI: 10.3390/ijms140917536] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
144 Ozgor D, Otan E. HCC and Tumor Biomarkers: Does One Size Fits All? J Gastrointest Cancer 2020;51:1122-6. [PMID: 32827068 DOI: 10.1007/s12029-020-00485-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Yu X, Xia H, Sun Z, Lin Y, Wang K, Yu J, Tang H, Pang D, Zhang Z. On-chip dual detection of cancer biomarkers directly in serum based on self-assembled magnetic bead patterns and quantum dots. Biosensors and Bioelectronics 2013;41:129-36. [DOI: 10.1016/j.bios.2012.08.007] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 7.9] [Reference Citation Analysis]
146 Hu Y, Zuo P, Ye BC. Label-free electrochemical impedance spectroscopy biosensor for direct detection of cancer cells based on the interaction between carbohydrate and lectin. Biosens Bioelectron 2013;43:79-83. [PMID: 23287651 DOI: 10.1016/j.bios.2012.11.028] [Cited by in Crossref: 73] [Cited by in F6Publishing: 57] [Article Influence: 8.1] [Reference Citation Analysis]
147 Yagmur E, Rizk M, Stanzel S, Hellerbrand C, Lammert F, Trautwein C, Wasmuth HE, Gressner AM. Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma. Eur J Gastroenterol Hepatol. 2007;19:755-761. [PMID: 17700260 DOI: 10.1097/meg.0b013e3282202bea] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
148 Gazzana G, Borlak J. Mapping of the serum proteome of hepatocellular carcinoma induced by targeted overexpression of epidermal growth factor to liver cells of transgenic mice. J Proteome Res. 2008;7:928-937. [PMID: 18198842 DOI: 10.1021/pr070462c] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
149 Saeki I, Yamasaki T, Tanabe N, Iwamoto T, Matsumoto T, Urata Y, Hidaka I, Ishikawa T, Takami T, Yamamoto N. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy. PLoS One. 2015;10:e0126649. [PMID: 25992784 DOI: 10.1371/journal.pone.0126649] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
150 Braicu C, Burz C, Berindan-Neagoe I, Balacescu O, Graur F, Cristea V, Irimie A. Hepatocellular Carcinoma: Tumorigenesis and Prediction Markers. Gastroenterology Res 2009;2:191-9. [PMID: 27942274 DOI: 10.4021/gr2009.07.1304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
151 Zekri AR, Bahnassy AA, Abdel-Wahab SA, Khafagy MM, Loutfy SA, Radwan H, Shaarawy SM. Expression of pro- and anti-inflammatory cytokines in relation to apoptotic genes in Egyptian liver disease patients associated with HCV-genotype-4. J Gastroenterol Hepatol. 2009;24:416-428. [PMID: 19054267 DOI: 10.1111/j.1440-1746.2008.05699.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
152 Chen LC, Liu MY, Hsiao YC, Choong WK, Wu HY, Hsu WL, Liao PC, Sung TY, Tsai SF, Yu JS, Chen YJ. Decoding the disease-associated proteins encoded in the human chromosome 4. J Proteome Res 2013;12:33-44. [PMID: 23256888 DOI: 10.1021/pr300829r] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
153 Yang JS, Qiao J, Kim JY, Zhao L, Qi L, Moon MH. Online Proteolysis and Glycopeptide Enrichment with Thermoresponsive Porous Polymer Membrane Reactors for Nanoflow Liquid Chromatography-Tandem Mass Spectrometry. Anal Chem 2018;90:3124-31. [DOI: 10.1021/acs.analchem.7b04273] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
154 Tahon AM, El-ghanam MZ, Zaky S, Emran TM, Bersy AM, El-raey F, A.z. E, El Kharsawy AM, Johar D. Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients. J Gastrointest Canc 2019;50:434-41. [DOI: 10.1007/s12029-018-0095-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
155 Melms JC, Thummalapalli R, Shaw K, Ye H, Tsai L, Bhatt RS, Izar B. Alpha-fetoprotein (AFP) as tumor marker in a patient with urothelial cancer with exceptional response to anti-PD-1 therapy and an escape lesion mimic. J Immunother Cancer 2018;6:89. [PMID: 30208947 DOI: 10.1186/s40425-018-0394-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
156 Helmy SA, El-mesery M, El-karef A, Eissa LA, El Gayar AM. Thymoquinone upregulates TRAIL/TRAILR2 expression and attenuates hepatocellular carcinoma in vivo model. Life Sciences 2019;233:116673. [DOI: 10.1016/j.lfs.2019.116673] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
157 Chaturvedi VK, Singh A, Dubey SK, Hetta HF, John J, Singh M. Molecular mechanistic insight of hepatitis B virus mediated hepatocellular carcinoma. Microbial Pathogenesis 2019;128:184-94. [DOI: 10.1016/j.micpath.2019.01.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
158 Nanashima A, Tobinaga S, Kunizaki M, Miuma S, Taura N, Takeshita H, Hidaka S, Sawai T, Nakao K, Nagayasu T. Strategy of treatment for hepatocellular carcinomas with vascular infiltration in patients undergoing hepatectomy. J Surg Oncol 2010;101:557-63. [PMID: 20213729 DOI: 10.1002/jso.21534] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
159 Abd El Gawad IA, Mossallam GI, Radwan NH, Elzawahry HM, Elhifnawy NM. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients. J Egypt Natl Canc Inst. 2014;26:79-85. [PMID: 24841158 DOI: 10.1016/j.jnci.2014.01.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
160 Thiesen AL. Hepatocellular Carcinoma in Adults. In: Sergi CM, editor. Liver Cancer. Exon Publications; 2021. pp. 39-54. [DOI: 10.36255/exonpublications.livercancer.2021.ch2] [Reference Citation Analysis]
161 Fartoux L, Decaens T. Contribution of biomarkers and imaging in the management of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2011;35 Suppl 1:S21-S30. [PMID: 21742297 DOI: 10.1016/s2210-7401(11)70004-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
162 Saxena R, Chawla YK, Verma I, Kaur J. Interleukin-1 polymorphism and expression in hepatitis B virus-mediated disease outcome in India. J Interferon Cytokine Res. 2013;33:80-89. [PMID: 23210983 DOI: 10.1089/jir.2012.0093] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
163 Levy M, Trivedi A, Zhang J, Miles L, Mattis AN, Kim GE, Lassman C, Anders RA, Misdraji J, Yerian LM, Xu H, Dhall D, Wang HL. Expression of glypican-3 in undifferentiated embryonal sarcoma and mesenchymal hamartoma of the liver. Hum Pathol 2012;43:695-701. [PMID: 21937079 DOI: 10.1016/j.humpath.2011.06.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
164 Li B, Feng W, Luo O, Xu T, Cao Y, Wu H, Yu D, Ding Y. Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma. Sci Rep 2017;7:5517. [PMID: 28717245 DOI: 10.1038/s41598-017-04811-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
165 Heringlake S, Hofdmann M, Fiebeler A, Manns MP, Schmiegel W, Tannapfel A. Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours. J Hepatol. 2010;52:220-227. [PMID: 20036025 DOI: 10.1016/j.jhep.2009.11.005] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 4.3] [Reference Citation Analysis]
166 Zhou Y, Wang B, Wu J, Zhang C, Zhou Y, Yang X, Zhou J, Guo W, Fan J. Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection. BMC Cancer 2016;16:506. [PMID: 27439521 DOI: 10.1186/s12885-016-2526-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
167 Morris SM, Carter KT, Baek JY, Koszarek A, Yeh MM, Knoblaugh SE, Grady WM. TGF-β signaling alters the pattern of liver tumorigenesis induced by Pten inactivation. Oncogene 2015;34:3273-82. [PMID: 25132272 DOI: 10.1038/onc.2014.258] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
168 Waidely E, Al-Yuobi AR, Bashammakh AS, El-Shahawi MS, Leblanc RM. Serum protein biomarkers relevant to hepatocellular carcinoma and their detection. Analyst. 2016;141:36-44. [PMID: 26606739 DOI: 10.1039/c5an01884f] [Cited by in Crossref: 40] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
169 Pavlovic N, Rani B, Gerwins P, Heindryckx F. Platelets as Key Factors in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1022. [PMID: 31330817 DOI: 10.3390/cancers11071022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
170 Behne T, Copur MS. Biomarkers for hepatocellular carcinoma. Int J Hepatol 2012;2012:859076. [PMID: 22655201 DOI: 10.1155/2012/859076] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 5.9] [Reference Citation Analysis]
171 Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A, Abbruzzese JL, Morris JS. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer. 2011;117:2478-2488. [PMID: 24048796 DOI: 10.1002/cncr.25791] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
172 Nel I, Baba HA, Weber F, Sitek B, Eisenacher M, Meyer HE, Schlaak JF, Hoffmann AC. IGFBP1 in epithelial circulating tumor cells as a potential response marker to selective internal radiation therapy in hepatocellular carcinoma. Biomark Med 2014;8:687-98. [PMID: 25123037 DOI: 10.2217/bmm.14.23] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
173 Hsieh CB, Chen TW, Chu CM, Chu HC, Yu CP, Chung KP. Is inconsistency of alpha-fetoprotein level a good prognosticator for hepatocellular carcinoma recurrence? World J Gastroenterol 2010;16:3049-55. [PMID: 20572309 DOI: 10.3748/wjg.v16.i24.3049] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
174 Grizzi F, Franceschini B, Fiamengo B, Russo C, Dioguardi N. Vascular architecture: is it a helpful histopathological biomarker for hepatocellular carcinoma? J Zhejiang Univ Sci B 2007;8:217-20. [PMID: 17444594 DOI: 10.1631/jzus.2007.B0217] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
175 Mir IH, Guha S, Behera J, Thirunavukkarasu C. Targeting molecular signal transduction pathways in hepatocellular carcinoma and its implications for cancer therapy. Cell Biol Int 2021. [PMID: 34270844 DOI: 10.1002/cbin.11670] [Reference Citation Analysis]